Watch out for an itchy, blistering rash with use of vildagliptin

+Practice

In print

Pharmacotherapy

Watch out for an itchy, blistering rash with use of vildagliptin

28 February 2024

By Linda Bryant and Tess James

Wednesday 28 February 2024, 12:40 AM

Over six months, Sam’s skin lesions became blisters [Image: Mohammad2018, CC BY-SA 4.0 via Wikimedia Commons]

This article looks at an autoimmune bullous skin disease that may occur spontaneously but can also be drug induced

Key points, Be alert for vildagliptin-induced skin reactions, even if it has been a long-term medicine used for up to five years. Even after discontinuation of , Pract Green w Pale Yellow

Medicines and Therapies

References

Phan K, Charlton O, Smith SD. Dipeptidyl peptidase-4 inhibitors and bullous pemphigoid: A systematic review and adjusted meta-analysis. Australas J Dermatol 2020;61(1):e15–21.
Silverii GA, Dicembrini I, Nreu B, et al. Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized controlled trials. Endocrine 2020;69(3):504–07.
Sun L, Wang C, Wu C, et al. Analysis of the clinical characteristics of dipeptidyl peptidase-4 inhibitor-induced bullous pemphigoid. Ann Pharmacother 2022;56(2):205–12.
Verheyden MJ, Bilgic A, Murrell DF. A systematic review of drug-induced pemphigoid. Acta Derm Venereol 2020;100(15):adv00224.

How to Treat

+How to treat

FREE READ

COPD: Prevent, treat and comfort

Respiratory physician Lutz Beckert considers chronic obstructive pulmonary disease management, including the prevention of COPD, the importance of smoking cessation and pulmonary rehabilitation, and the lifesaving potential of addressing treatable traits. He also discusses the logic of inhaler therapy, moving from single therapy to dual and triple therapy when indicated, as well as other aspects of management

Wednesday 26 March 2025, 12:50 AM